MGTX

MeiraGTx Holdings plc

Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001735438 Biotech & Drug Discovery

$9.18 −0.03 (−0.33%)

Oct 26 4:00 PM ET · prev $9.21

Market cap

$938.3M

Small cap

Consensus

Buy

86% Buy or better · 14 analysts

Median target

$23.50

+156% · range $16.00–50.00

Next earnings

Nov 18

in 22 days · EPS est. −$0.47

1 year

+3.5%

from $8.87 · Oct 27

30 days

−17.4%

from $11.11

52-week range

$6.99–14.97

−39% from high · low Mar 5

Avg volume 20D

891.9K

Oct 7 spike 2.31M

Short interest

🔒 Subscribers only

Insider net

−$4.7M

0 buyers · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 6 reports · 90 days

Balance 0 bearish · 0 bullish · 6 neutral oldest → newest, height = score

Avg score

·High conf. 4/6 ·Next Earnings date, Nov 18, 2026

Strongest NEUTRAL Stuart Naylor, an officer of MeiraGTx Holdings plc, filed a Form 144 on October 6, 2026, indicating intent…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

E Apr 16 FDA: MeiraGTx Announces Positive Three-year Data from the Phase…
R Jul 7 MeiraGTx entered into a $400M strategic financing with Oberland Capi…
S Jul 21 1 insider sell $700.6K at $12.51
S Aug 18 1 insider sell $859.3K at $13.86
A Sep 24 Goldman Sachs initiates
X Sep 30 Short interest jumps 49.5% to 6.00M
S Oct 6 1 insider sell $294.3K at $10.64
S Oct 20 1 insider sell $557.2K at $9.95

Signal stack

Where each data set points today.

InsidersBEARISH

3 insiders sold $4.7M.
InstitutionsBULLISH

Q2 2026: 38 added (0 new), 6 trimmed or exited.
AnalystsBULLISH

12 of 14 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.500 → −$0.473 over 90 days. 2 up, 0 down in 30 days.
TrendDOWNTREND

24% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
Rubric Capital Management LP	ADD	9,100,000	$122.9M
BlackRock, Inc.	ADD	4,757,178	$64.3M
Woodline Partners LP	DOUBLED	1,500,135	$20.3M
STATE STREET CORP	ADD	1,393,222	$18.8M
JACOBS LEVY EQUITY MANAGEMENT, INC	DOUBLED	1,015,106	$13.7M
D. E. Shaw & Co., Inc.	DOUBLED	852,902	$11.5M
GEODE CAPITAL MANAGEMENT, LLC	ADD	849,082	$11.5M
VANGUARD PORTFOLIO MANAGEMENT LLC	ADD	723,563	$9.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts

Buy 86% rate it Buy or better

Strong Buy4Buy8Hold2Sell0Strong Sell0

12-month targets · 8 analysts

$9.18 $16.00 $23.50 $50.00

Price is below the lowest target. Median implies +156%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 24, 2026	Goldman Sachs INITIATE	INITIATE	Neutral
Aug 14, 2026	RBC Capital MAINTAIN	MAINTAIN	Outperform
Jul 8, 2026	RBC Capital MAINTAIN	MAINTAIN	Outperform
Jul 8, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
May 15, 2026	RBC Capital MAINTAIN	MAINTAIN	Outperform

Insider ledger

Form 4

bought · 0 insiders

$4.7M

sold · 3 insiders

Date	Insider	Type	Value
Oct 20, 2026	Giroux Richard CFO & COO	SELL	$557.2K
Oct 6, 2026	Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY	SELL	$294.3K
Sep 23, 2026	SEBULSKY ALAN Director	AWARD	100,000 sh
Aug 18, 2026	Forbes Alexandria PRESIDENT & CEO	SELL	$859.3K
Jul 21, 2026	Giroux Richard CFO & COO	SELL	$700.6K
Jul 7, 2026	Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY	SELL	$35.3K
Jul 7, 2026	Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY	SELL	$374.2K
Jun 25, 2026	Forbes Alexandria PRESIDENT & CEO	AWARD	980,000 sh

Earnings setup

Estimates

Nov 18

reports in 22 days

−$0.47

EPS estimate, this quarter

+5%

estimate change, 90 days

2↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.500

90d

−$0.488

60d

−$0.455

30d

−$0.455

−$0.473

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.47	-$0.53–-$0.38	-4.0%	$7.0M
Next Q	-$0.50	-$0.57–-$0.39	-4.9%	$8.5M
Current FY	$0.51	$0.07–$0.98	+0.0%	$337.1M
Next FY	-$1.52	-$1.98–-$0.70	-9.7%	$66.9M